<DOC>
	<DOCNO>NCT01542476</DOCNO>
	<brief_summary>This study conduct Europe . The aim study assess well-being patient follow treatment insulin detemir ( Levemir® ) subject type 1 type 2 diabetes either initiation switch insulin treatment long-acting basal insulin analogue need .</brief_summary>
	<brief_title>The Impact Initiating/Switching Insulin Detemir Emotional Well-being Treatment Satisfaction</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Any subject type 1 type 2 diabetes optimally control ( HbA1c 7.5 % ) discretion participate physician decide either initiate switch treatment longacting insulin analogue Subjects type 1 diabetes treat insulin least 12 month Potential prestudy treatment insulin detemir ( Levemir® ) start two month baseline</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>